Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil Sharrack

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Journal of Neurology|May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging studyIan Marshall, Michael J Thrippleton, Mark E Bastin, et al.
JAMA|January 16, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialRichard K Burt, Roumen Balabanov, Joachim Burman, et al.
Bone Marrow Transplantation|September 30, 2025
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working partyRaffaella Greco, Riccardo Saccardi, Marta Ponzano, et al.
The International Journal of Behavioral Nutrition and Physical Activity|November 22, 2025
Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?Joren Buekers, Julia Chernova, Sarah Koch, et al.
Eclinicalmedicine|February 16, 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeRaffaella Greco, Tobias Alexander, Nicoletta Del Papa, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
Trials|January 17, 2026
Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristicsGavin Brittain, Ellen Buckley, Vita Lanfranchi, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Journal of Neurology|May 31, 2018
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging studyIan Marshall, Michael J Thrippleton, Mark E Bastin, et al.
JAMA|January 16, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical TrialRichard K Burt, Roumen Balabanov, Joachim Burman, et al.
Bone Marrow Transplantation|September 30, 2025
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working partyRaffaella Greco, Riccardo Saccardi, Marta Ponzano, et al.
The International Journal of Behavioral Nutrition and Physical Activity|November 22, 2025
Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?Joren Buekers, Julia Chernova, Sarah Koch, et al.
Eclinicalmedicine|February 16, 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeRaffaella Greco, Tobias Alexander, Nicoletta Del Papa, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
Trials|January 17, 2026
Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristicsGavin Brittain, Ellen Buckley, Vita Lanfranchi, et al.
Brain : a Journal of Neurology|October 8, 2021
The impact of smoking cessation on multiple sclerosis disease progressionJeff Rodgers, Tim Friede, Frederick W Vonberg, et al.
Pageof 16